This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Jegger, D Articles by von Segesser, L K Search for Related Content PubMed PubMed Citation Articles by Jegger, D Articles by von Segesser, L K Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Blood Thinners Hazardous Substances DB HEPARIN PROTAMINE Social Bookmarking                         What's this?

Assembly of the Heparin Removal Device for patients with suspected adverse reaction to protamine sulphate

Department of Cardiovascular Surgery, University Hospital, Lausanne, david.jegger{at}chuv.hospvd.ch

H T Tevaearai

Department of Cardiovascular Surgery, University Hospital, Lausanne

J Horisberger

Department of Cardiovascular Surgery, University Hospital, Lausanne

X M Mueller

Department of Cardiovascular Surgery, University Hospital, Lausanne

I Seigneuil

Department of Cardiovascular Surgery, University Hospital, Lausanne

N Pierrel

Department of Cardiovascular Surgery, University Hospital, Lausanne

Y Boone

Department of Cardiovascular Surgery, University Hospital, Lausanne

L K von Segesser

Department of Cardiovascular Surgery, University Hospital, Lausanne

Protamine sulphate is routinely used after cardiopulmonary bypass (CPB) to restore the patient’s baseline coagulatory state. However, adverse reactions are encountered, and alternative means to neutralize heparin are, therefore, necessary. The Heparin Removal Device (HRD) constitutes an extracorporeal circuit that allows ex vivo deheparinization by mean of a polycationic ligand that binds heparin molecules.

This paper presents the setup of the HRD circuit. It is illustrated by the report of a 68-year-old man with a known severe crustacean allergy. The patient (78 kg, 170 cm) was admitted for elective coronary artery bypass graft surgery. It was decided that the HRD would be used as a precaution in order to avoid the risks of using protamine sulphate. The CPB time and aortic crossclamp time were 70 and 40 min, respectively. At the end of CPB, the device was inserted and processing started. Activated coagulation time values were monitored over a 130 min period and diminished from 480 to 300 s after 45 min, 220 s after 90 min, and settled at 150 s. Haemostasis was acceptable and processing stopped. The operation was terminated and the patient transferred to the intensive care unit. Clinical evolution was excellent, with minimal postoperative bleeding.

The HRD presents an alternative to protamine sulphate when this drug is contraindicated for a certain patient population who might have a suspected, known or emergency adverse reaction.

Perfusion, Vol. 15, No. 5, 453-456 (2000)
DOI: 10.1177/026765910001500508


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?